Karl Christian Heller
Chief Executive Officer at Freeline Therapeutics GmbH
Profile
Karl Christian Heller currently works in Freeline Therapeutics GmbH as a Co-Managing Director.
Karl Christian Heller active positions
Companies | Position | Start |
---|---|---|
Freeline Therapeutics GmbH
Freeline Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Ascend Gene & Cell Therapies Ltd., Freeline Therapeutics GmbH is a German biotechnology company that focuses on liver directed gene therapies for bleeding disorders and other chronic diseases. The company is based in Planegg, Germany. The company has a pipeline of gene therapies that have the potential to change the lives of people with chronic, debilitating diseases. Freeline has two key enabling platforms critical to realizing AAV gene therapy across its indications\: its proprietary AAV vector platform and its high-performing manufacturing platform. The company was founded in 2015, and the CEOs are Markus Hörer and Karl Christian Heller. Freeline Therapeutics was acquired by Ascend Gene & Cell Therapies Ltd. from Freeline Therapeutics Holdings Plc on February 10, 2023 for $25.83 million. | Chief Executive Officer | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Freeline Therapeutics GmbH
Freeline Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Ascend Gene & Cell Therapies Ltd., Freeline Therapeutics GmbH is a German biotechnology company that focuses on liver directed gene therapies for bleeding disorders and other chronic diseases. The company is based in Planegg, Germany. The company has a pipeline of gene therapies that have the potential to change the lives of people with chronic, debilitating diseases. Freeline has two key enabling platforms critical to realizing AAV gene therapy across its indications\: its proprietary AAV vector platform and its high-performing manufacturing platform. The company was founded in 2015, and the CEOs are Markus Hörer and Karl Christian Heller. Freeline Therapeutics was acquired by Ascend Gene & Cell Therapies Ltd. from Freeline Therapeutics Holdings Plc on February 10, 2023 for $25.83 million. | Commercial Services |
- Stock Market
- Insiders
- Karl Christian Heller